DEA places new anesthesia drug cipepofol in Schedule IV
/ 1 min read
Table of Contents
The Drug Enforcement Administration (DEA) has issued an interim final rule placing cipepofol, marketed as Cypsedo, in Schedule IV of the Controlled Substances Act. This follows the Food and Drug Administration’s approval of the drug on May 29, 2026, for inducing general anesthesia in adults undergoing surgery.
Why it matters: This is a standard administrative step required when a new drug with controlled substance properties is approved. It does not change how the drug is prescribed or used, but it establishes the legal framework for its distribution, storage, and record-keeping. For most people, this is a background compliance update rather than a change in access or safety.
Who it affects
- Anesthesiologists and surgeons who prescribe or administer Cypsedo
The action was taken by the Drug Enforcement Administration and published in the Federal Register; readers should consult the original document for specific compliance deadlines and comment periods.
Agency: Justice Department, Drug Enforcement Administration
Source: Federal Register — read the official document